Top ▲

Diabetes mellitus, insulin-dependent; IDDM

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:1032
Name:Diabetes mellitus, insulin-dependent; IDDM
Associated with:3 targets
1 immuno-relevant ligand
Synonyms
Type 1 diabetes mellitus
Database Links
Disease Ontology: DOID:9744
OMIM: 222100

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols
CIITA
NLRP1
regulator of G-protein signaling 1
References:  2

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖
Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
teplizumab
Immuno Disease Comments: Approved drug: Delays immune-mediated damage of pancreatic β cells and preserves insulin production in the early stages of T1DM.
Clinical Use: Early clinical evidence indicated a propensity towards preventive efficacy in individuals at risk of developing type 1 diabetes [1]. Approved in 2022 to delay the onset of stage 3 type 1 diabetes. was investigated for anti-inflammatory activity in moderate to severe psoriasis, but injection site reactions lead to termination in this disease. | View clinical data
Bioactivity Comments: Teplizumab's CD3e binding affinity will be similar to that of its parent antibody . | View biological activity

References

Show »

1. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS et al.. (2019) An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med, 381 (7): 603-613. [PMID:31180194]

2. Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, Yang JH, Howson JM, Stevens H, McManus R, Wijmenga C et al.. (2008) Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med, 359 (26): 2767-77. [PMID:19073967]